ForPatients
by Roche

LeukemiaNon Hodgkin Lymphoma (NHL)Lymphoma

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Country	NCT03289182 ML39600

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

Post-Marketing Surveillance of MabThera Subcutaneous in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Trial Summary:

This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.

Hoffmann-La Roche	N/A
Sponsor	Phase

NCT03289182 ML39600
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	# 19 Years	No

Inclusion Criteria:

- Participants administered with MabThera subcutaneously within the approved indication in Korea
- Participants previously untreated with MabThera subcutaneously

Inclusion Criteria for NHL participants for MabThera subcutaneously 1400mg:

- Relapsed or chemoresistant follicular lymphoma (FL) (B, C, and D type by international working formulation classification of B-cell NHL) participants
- Previously untreated FL participants in combination with chemotherapy
- Participants who are treated with maintenance therapy after the treatment of FL participants responding to induction therapy.
- Cluster of differentiation 20-positive, diffuse large B-cell NHL participants in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (8 cycles) chemotherapy

Inclusion Criteria for CLL participants for MabThera subcutaneously 1600mg:

- Previously untreated or relapsed/refractory CLL participants in combination with chemotherapy

Exclusion Criteria:

- Pregnant or breastfeeding women
- Participants who are out of locally approved indications, dosage, and administration including medication error
- Contraindication in use by locally approved indications, dosage, and administration